Research programme: serotonin 3 receptor antagonists - Rottapharm

Drug Profile

Research programme: serotonin 3 receptor antagonists - Rottapharm

Alternative Names: CR-3124

Latest Information Update: 24 Feb 2010

Price : $50

At a glance

  • Originator Rottapharm
  • Class
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Drug abuse; Fibromyalgia; Inflammatory bowel diseases; Nausea and vomiting

Most Recent Events

  • 05 Dec 2006 CR 3124 is available for licensing (http://www.rotta.com/pages/index.asp)
  • 05 Dec 2006 Preclinical trials in Drug abuse in Italy (unspecified route)
  • 05 Dec 2006 Preclinical trials in Fibromyalgia in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top